With more than 3.0 million page views and more than 5,000 items, this blog provides news and commentary on public policy, business and economic issues related to the $3 billion California stem cell agency. David Jensen, a retired California newsman, has published this blog since January 2005. His email address is djensen@californiastemcellreport.com.
California's plan to create an ambitious, $150 million public/private partnership to commercialize state-funded stem cell research edged forward this week as the deadline for applications closed on Monday afternoon.
Little is known about the nature of the applications -- not even the number received. The state's stem cell agency yesterday declined to reveal the figure, declaring that the proposals needed to be examined to determine eligibility.
Traditionally the $3 billion agency does not disclose the names of applicants for its funding or details of their applications, although there have been exceptions. Their proposals are reviewed behind closed doors by scientific grant reviewers whose names are not disclosed. Nor are the reviewers' statements of economic interest publicly revealed.
A CIRM document calls for the proposal to be evaluated by reviewers during the first quarter of next year with final board action also coming during that period. The recommendations of reviewers are almost never overturned by the board.
The public/private partnership could well be one of the landmark legacies of the stem cell agency, formally known as the California Institute for Regenerative Medicine(CIRM). The project would be unique in California history and nationally.
The eligibility requirements include the following:
A California location for the work
Documentation of an "upfront financial commitment" of $75 million(no in-kind services)
Readiness to begin work as required by CIRM
Incorporation by the date of the application
The recipient must begin work on the project within 45 days of the award, which translates to before the middle of next year.
You might say it is a case of "self-control" involving the test of a stem cell therapy for an infamous and terrible disease.
Not self-control in the usual sense, but in the sense of controls during a clinical trial for a treatment prior to its release to the general public.
Clive Svendsen (left) during 2013 visit to Cedars-Sinai
by famed physicist Stephen Hawking (seated), who .
has ALS. Photo Eric Reed/Cedars-Sinai
The key scientist involved in the trial is Clive Svendsen at Cedars-Sinai in Los Angeles. He and his team have just received the federal go-ahead for the test of a therapy for amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease. Approval came after a 4,600-page application was submitted.
Research leading to the trial has been heavily funded by California's $3 billion stem cell agency. About $17 million has been awarded to Svendsen related to the project, which is tackling what is a truly frightful affliction.
As Kevin McCormack, senior communications director for the stem cell agency, put it this morning in an item on the agency's blog:
"People with ALS lose the ability to speak, eat, move and finally,
breathe. The average life expectancy after diagnosis is just 3 – 4
years. It’s considered an orphan disease because it affects only around
30,000 people in the US; but even with those relatively low numbers that
means that every 90 minutes someone in the US is diagnosed with ALS,
and every 90 minutes someone in the US dies of ALS."
Normally in clinical trials, a treatment is tested on two groups of patient. One group receives the treatment. The other, control group does not,. McCormack explained how Svendsen's trial will work.
"In this clinical trial the patients will serve as their own control
group. Previous studies have shown that the rate of deterioration of
muscle movement in the legs of a person with ALS is the same for both
legs. So Svendsen and his team will inject specially engineered stem cells into a portion of the spine that controls movement on just one
side of the body. Neither the patient nor the physician will know which
side has received the cells. This enables the researchers to determine
if the treated leg is deteriorating at a slower rate than the untreated
leg."
The agency, formally known as the California Institute for Regenerative Medicine (CIRM), quoted its chairman Jonathan Thomas in news release as saying,
“The disease affects around 30,000 people in the US, too small a number
to make it economically viable for many companies to develop a
treatment. Fortunately, the people of California created CIRM to get
around problems like that. Our goal is not to make money. Our goal is to
save lives."
"The stem cell implantations for ALS patients involved in the clinical trial could begin by the end of the year, Svendsen said. Participants will come from the ALS Clinic at Cedars-Sinai, and the trial will be led by Robert Baloh, MD, PhD, and Peggy Allred, PT, DPT. The neurosurgical team will be led by J. Patrick Johnson, MD, MS."
Patients interested in the trial should call Cedars at 310-423-1791.
The California stem cell agency on Wednesday completed creation of a $30 million effort to dramatically speed approval of stem cell therapies and establish the Golden State globally in the much-heralded regenerative medicine field.
Dubbed the “pitching machine,” the two-part program is designed to pick up where basic stem cell research leaves off and to accelerate it through the all-important clinical trials involving humans. Such trials are required prior to widespread use of a therapy by the public and generally take years.
With no debate, no questions and no discussion Wednesday, the governing board of the stem cell agency unanimously approved a $15 million award to QuintilesIMS in San Diego to help move basic research into clinical trials. The effective decision, however, was made Oct. 4 during a closed-door meeting of the agency’s scientific reviewers, who gave the proposal a score of 89 out of 100.
The other half of the pitching machine was an additional $15 million award to Quintiles, which formally began operations this month. Quintiles is a publicly traded, multinational firm based in Durham, N.C., that deals with “information and technology solutions” in health care.
C. Randal Mills, president of the $3 billion stem cell agency officially known as the California Institute for Regenerative Medicine, said the pitching machine is likely to be the most significant achievement of the state’s 12-year-old research effort.
CIRM’s contracts with Quintiles call for the $30 million to be spent in California.
California voters created the state’s stem cell agency in 2004 following a ballot initiative in which voters were told that stem cell cures were nearly at hand. The agency has yet to finance research that has produced a therapy that is available for widespread use.
Quintiles’ responsibilities will include pharmacology and toxicology studies along with manufacturing stem cell and gene-modified stem cell products. The company will also provide clinical trial operations and management services as well as data management, and biostatistical and analytical services.
CIRM’s contracts with Quintiles are for five years. The effort will also feed into the agency’s Alpha Clinics, a $34 million program to intensify focus on stem cell treatments and to contribute to California’s global position in the stem cell field.
The agency said Wednesday’s action will create “the first center in the world designed specifically to overcome the unique challenge of manufacturing, safety testing and other activities needed to successfully apply” to start a stem cell clinical trial. One clinical trial that launched in 2010 required submission of 22,000 pages of information to the FDA.
CIRM said Quintiles’ expertise will create “a standardized, uniform approach that best meets the needs of the FDA, making it easier for the agency to evaluate projects in a timely manner.”
Mills said that with the $30 million Quintiles deal, “we are doing a lot more than just funding research. We have created an entire infrastructure, unique to California, that will help us increase the volume, speed and quality of projects moving into clinical trials.”
CIRM is involved in 19 active clinical trials. It is projecting its participation in about 50 more before 2020, when its funding is scheduled to run out. No additional source of funding has been secured.
(Editor's note: On Oct. 21, the agency said its list of active clinical trials had now reached 22. The agency's web page on the list of clinical trials should be updated soon. )
Read more here: http://www.sacbee.com/news/local/article109286937.html#storylink=cpy
Juan Carlos Izpisúa Belmonte in Murcia, Spain, in 2015
El Mundo photo
The ongoing tale of pigs, people and their organs moved along during the weekend with a fresh chapter about a Spaniard and the Salk Institute in La Jolla, Ca.
Izpisúa Belmonte has a lab at Salk and another in Spain. Fikes reported that the researcher received a $2.5 million award from the National Institutes of Health last week "to advance his research with monkey cells implanted into pig embryos."
Fikes wrote,
"Since monkeys are biologically similar to humans, analysis of pig-monkey chimeras should yield insights that can be applied to eventual production of human organs, he said. And unlike mice, pigs are large enough to grow usable human organs."
In Spain, Fikes said, Izpisua Belmonte is forging ahead at the same time with human-pig work.
The research is touchy for obvious reasons. But Fikes wrote that "the shortage of organs that causes nearly two dozen Americans — and many others around the world — to die each day while awaiting a transplant."
Izpisúa Belmonte is making progress, according to the newspaper report. Fikes wrote,
"After years of experiments, in 2015 his team reported success in coaxing a newly identified type of human stem cell to not only live in mouse embryos, but also integrate into the embryos’ structure. Those embryos weren’t allowed to develop further because of U.S. regulations."
Izpisúa Belmonte has received $6.5 million in three awards from the California stem cell agency, but none of those grants are currently active.
CIRM graphic and text on its pitching machine, consisting of the translating
and accelerating centers. Discovery is basic research.
Highlights Application scored at 89 Dramatic reductions in time expected Unusual 'trinity' support
California's stem cell agency next week is set to approve the second part of a $30 million "pitching machine" aimed at accelerating stem cell research and translating it into therapies that can save people's lives.
An as yet-to-be-identified organization will receive $15 million under the proposal (INFR2-09298) to be considered publicly by the full board of the California Institute for Regenerative Medicine (CIRM), as the Oakland-based state agency is formally known.
The plan has already been enthusiastically endorsed by CIRM's out-of-state scientific reviewers who gave it a score of 89 out of 100 in a closed-door session, according to a CIRM summary of the review. The CIRM board almost never overturns a decision by its reviewers.
A competing proposal (INFR2-09233), also considered behind closed doors, was rejected by reviewers. They gave it a score of less than 60, declaring that the application did not focus on the agency's objectives but rather on the unidentified applicant's proprietary technology.
The "pitching machine" description came from Randy Mills, president of the stem cell agency, who last December told the CIRM board last December that the agency should dramatically reduce the number of years it takes for a stem cell therapy to reach patients.
CIRM photo and text
One-half of the machine -- the accelerating center -- involves a $15 million contract with QuintilesIMS. Last week, the company formally kicked off its new operations on behalf of CIRM in
San Diego. Speaking at the ceremonies for the opening, Mills said the intent was to create "a center for the world’s most brilliant researchers and innovators in cell therapy that gives them the tools they need to successfully navigate this regulatory system."
The agency said Quintiles will provide support and management services that scientists need to boost the chances that their clinical trials will be successful. Conventional clinical trials can have a 90 percent failure rate. The presumption is that stem cell clinical trials, which are relatively new, are likely to have a higher failure rate.
The $15 million award next week will create a translating center to work with the accelerating center being run by Quintiles.
"There's a lot of opportunity in this translational phase for us to go after. We can literally cut this phase in half. So the research centers are excited about it, and the FDA was excited about it, and I was excited about it. And that's a very, very unusual trinity to have."
CIRM said in the review summary,
"Our ultimate goal is to empower the translating center and other elements of CIRM infrastructure to become the premier enabler of cell based therapies to patients in California and worldwide."
Next week's one-hour board meeting will be held telephonically with locations from which the public can participate in Oakland, San Diego, Napa, Fresno, Santa Barbara, Los Gatos, Sacramento, Irvine and San Francisco. The session will be audiocast online and via an 800 number. Addresses and directions can be found on the agenda.
One of the great abominations of our time -- at least in the view of this curmudgeonly writer -- is the nearly endless list of "special days" that seem to parade without stop throughout the year.
I take that back. The list is not nearly endless. A web site called Track Maven has counted something like 2,300 "special" or "national" days. And -- most importantly -- the list does not include today, Oct. 12, as Stem Cell Awareness Day.
This year, according to the quasi-official list, today, Oct. 12, is actually limited to marking the following occasions: National Free Thought Day, National Farmer’s Day, National Gumbo Day, National Fossil Day (Wednesday of second full week in October), National Emergency Nurse’s Day (second Wednesday in October), National Bring-Your-Teddy Bear-to-Work/School Day (second Wednesday in October) and National Stop Bullying Day (second Wednesday in October).
Stem cells are quite clearly missing from the entire Track Maven list. There is a National Brisket Day (May 28), National Cabbage Day (Feb. 17), National Public Sleeping Day (Feb. 28), National Absinthe Day (March 5) and National Get-Over-It Day (March 9). But definitely no stem cell day.
So why is the California Stem Cell Report writing about this when there are so many more important things to discuss? Because California's $3 billion stem cell agency conjured up its Stem Cell Awareness Day a few years back and can't seem to shake loose of the concept.
The reality of these not-so-special days is that they originate as a feeble tool of public relations practitioners to appear to gin up some attention for the clients and pad out an invoice. The most effective thing the special days do is fill the mail boxes of the running dogs of the media, who pitch them in the trash without even opening the envelope or the email.
That said, UC Davis stem cell researcher Paul Knoepfler bit on the ploy. He actually put together a useful overview on his blog of the state of the stem cell arena, albeit tilted toward the optimistic.
Meanwhile, today this curmudgeon is going to celebrate National Grouch Day, which is supposed to be on this Saturday but is going to be extended this year to a four-day holiday by unanimous consent.
(Late-breaking development: As per my usual practice with organizations, I notified Track Maven that
it was mentioned in an item today on the California Stem Cell Report.
Here is their response, and Stem Cell Awareness Day is now officially quasi-official: "Thanks for bringing National Stem Cell Awareness Day to our attention. You'll see I've updated our post to include it. Appreciate the feedback. Warmly, Kara")
It was an interesting juxtaposition today on Twitter -- a vision of stem cell hope vs. a reality check.
The apparent contradiction is not uncommon in health science news.
It is a variation of the glass half-full or half-empty expression. But the stakes are not trivial. They involve deep emotions and the finances of the patients who face decades of impairment and death.
The perspectives also involve the mindsets of researchers and entities such as the $3 billion California stem cell agency. It has been wrestling for 12 years with the problem of producing a viable stem cell therapy for any sort of affliction. Its funds could well run out -- as expected in about three years -- with no cure to demonstrate for California voters who created the program in 2004.
Should the agency and researchers surrender because the task is enormous and is likely not to bear real fruit during their lifetimes? Should they move on -- if they could -- to something that would provide a more immediate, major public health benefit.
Can or should taxpayers support what some might call dreamy scientific aspirations while the state could use the billions to improve education and daily medical care for the poor?
Some may be able to come up with firm, black-and-white answers to these sort of policy and personal -- at least for researchers -- questions. This writer cannot.
As for the agency, its funds are legally locked for stem cell research or something akin to it. All the agency can do is spend the money well in that area -- a restriction approved by voters in the ballot initiative process.
Meantime, the public is hit with contradictory messages, becomes cynical and less ready to back research. All part of the challenge that faces patient advocates, researchers and drug companies today.
A California scientist has plunged into the jungle of 4,000-plus comments dealing with the federal government's proposal to change regulation of stem cell research and has discovered an intense sense of ownership on the part of many.
"In fact more than 700 use the exact same phrase 'My cells are MY cells' and it looks like hundreds more comments have the exact same or similar
language is used in more extensive forms. 'My cells are my property.' 'My cells are mine.'"
In all, Knoepfler said that the Food and Drug Administration(FDA) had received 4,251 comments by the time the comment period closed. The comments showed a clearly organized effort by one segment of the public. He said the general sense of many was:
"Keep your hands off my cells!"
Knoepfler wrote,
"It would seem the point is that these particular commenters believe
that cells taken from their bodies should not be regulated as drugs
under any circumstances.
"Everyone is of course entitled to their own opinion, but cells can be
drugs if they are changed or used in ways that are not homologous
because these factors make them have higher risk to patients. To ask for
cells to never be regulated as drugs is asking for chaos and many harms
to patients, but people may not realize that."
California's $3 billion stem cell agency is among those seeking changes in the FDA guidelines. The FDA has not set a public timetable for action on new rules, which Knoepfler and others have said are needed to deal with "an out-of-control, direct-to-consumer stem cell clinic industry."
Knoepfler surveyed the industry earlier this year and reported nearly 600 unregulated clinics operating nationwide. It was the first time that the size of the industry has been documented.++
The Semma-Melton diabetes item on Sept. 29, 2016, contained an inaccurate and incomplete description of the roles of institutions involved in the work being funded by the California stem cell agency. The item has been corrected. Here is the now accurate paragraph in question.
"Peter Butler, chief of Endocrinology, Diabetes and Hypertension at UCLA, will be dealing with patient selection. Dhruv Sareen of the Induced Pluripotent Stem Cell Core Facility at Cedars-Sinai will direct derivation and analysis of pluripotent stem cells from each
patient’s blood. The cells will be transferred to the City of Hope for
manufacture of products for clinical trials."
An eminent Harvard stem cell researcher who is searching for a cure for an affliction that plagues 29 million Americans stood on a San Francisco stage this week and spoke of "things we don't understand."
Doug Melton, photo Harvard Gazette/B.D. Colen
The scientist is Doug Melton, who is on a deeply personal quest for a cure for diabetes. Both of his children have the disease. And the state of California is helping out on his search with $5 million.
The occasion for Melton's remarks was the presentation of the Ogawa-Yamanaka Stem Cell Prize, a $150,000 award for his work in cellular reprogramming.
Here is how Hannah Robbins of the Harvard Gazettedescribed the results of Melton's research:
"As a pioneer in programming insulin-producing beta cells from stem cells, Melton’s lab can now generate therapeutic quantities of functional, stem cell-derived beta cells, which Melton hopes will someday soon replace the life-saving yet painful daily insulin injections for diabetics."
The $5 million from California is a grant made last March by the state's $3 billion stem cell agency, formally known as the California Institute for Regenerative Medicine (CIRM).
The cash is going to a firm in Cambridge, Ma., called Semma Therapeutics, Inc., which Melton co-founded and which is named after his two children, Sam and Emma. Melton now serves on the firm's board of directors. The business is only two years old, but has raised roughly $50 million to translate Melton's work into actual treatments.
His grant application to CIRM in March was titled simply "Personalized Cell Therapy for Diabetes." The proposal (application number TRAN1-08561) received a score of 90 out of 100 from the agency's scientific reviewers who are from out-of-state. A summary of the closed-door review said the proposal was "strong, well-designed, feasible. and high impact." The research "has excellent product development plans and great regulatory support," reviewers said.
The stem cell agency is limited to funding only work that is done in California. Semma announced earlier this month that it has set up arrangements with UCLA, Cedars-Sinai and the City of Hope in the Los Angeles area to generate "suitable clinical grade" cells from patients and "to establish a path leading to the transplantation of these cells back into patients in a clinical trial."
Peter Butler, chief of Endocrinology, Diabetes and Hypertension at UCLA, will be dealing with patient selection. Dhruv Sareen of the Induced Pluripotent Stem Cell Core Facility at Cedars-Sinai will direct derivation and analysis of pluripotent stem cells from each patient’s blood. The cells will be transferred to the City of Hope for manufacture of products for clinical trials.
Overseeing the entire project is Felicia Pagliuca, principal investigator on the CIRM grant. She is also scientific co-founder of the firm, the vice president of Cell Biology Research and Development and a lead on the original research in Melton's lab.
Felicia Pagliuca and Robert Millman
photo Boston Globe/Dina Rudick
The financial backers are led by MPM, a venture capital firm with offices in South San Francisco and Cambridge, Mass. Robert Millman, formerly of MPM, is CEO of Semma. Other investors include Medtronic, Novartis, Fidelity Biosciences, Arch Venture Partners and the Juvenile Diabetes Foundation.
Semma is still hiring and has openings listed for five positions on its web site, ranging from scientists to a director of device development and manufacturing.
Here is a video recording of the award ceremony in which Melton discusses his research and "the things we don't understand" in the science.
(Editor's note: An earlier version of this story contained an inaccurate description of the roles of Cedars-Sinai and the City of Hope involving the CIRM-funded work.)
Kris Boesen, patient in Asterias trial -- photo from CIRM
One could say that the latest news involving human embryonic stem cell research and the California stem cell agency stretches back nearly 27 years.
It was then -- in 1990 -- that Geron, Inc., was incorporated by Michael West who began what eventually turned into a quest for a stem cell therapy for treatment of spinal cord injury.
Yesterday, the Golden State's stem cell research effort carried an item on its blog, The Stem Cellar, dealing with the latest chapter in that quest. The headline said,
"Full Steam Ahead: First Patient is Dosed in Expanded CIRM Spinal Cord Injury Trial"
In the piece, Karen Ring, website manager for the stem cell agency, celebrated the latest patient news concerning the trial which is backed by a Menlo Park, Ca., company called Asterias Biotherapeutics. Ring said,
"Inspiring stories like that of Kris Boesen, who was the first AIS-A patient to get 10 million cells in the Asterias trial and now has regained the use of his arms and legs, are the reason why CIRM exists and why we are working so hard to fund promising clinical trials. If we can develop even one stem cell therapy that gives patients back their life, then our efforts here at CIRM will be worthwhile."
Michael West, Biotime photo
The tale of Michael West, his research and his companies is long and convoluted. The short version is that he is now co-CEO of Biotime, Inc., of Alameda, Ca., which spawned in 2012 Asterias Biotherapeutics, Inc., of Menlo Park, Ca.
Geron is out of the business of human embryonic stem cell research. In 2011, it abandoned the nation's first-ever hESC trial for financial reasons. The effort was sold to Asterias in 2013. In 2014, the $3 billion California stem cell agency jumped in with $14.3 million for Asterias.
Asterias' stock closed at $4.56 yesterday. Its 52-week high stood at $5.75. Its 52-week low was $2.30.
A San Diego television station this week aired a solid series exploring the world of unproven stem cell treatments, including therapies in Mexico and involving a California company.
The work was produced on KBPS by David Wagner and ran as a two-part series(see image above). UC Davis researcher Paul Knoepfler, who earlier this year documented the existent of 570 unregulated stem cell clinics nationally, described Wagner's work as "an important new piece...on for-profit investigational stem cell treatments."
Companies mentioned by Wagner included Stemedica Cell Technologies, Inc., Global Stem Cell Health, Inc., both in the San Diego area, and Hospital Angeles in Tijuana, just south of San Diego in Mexico.
Stemedica is the firm connected to nationally reported treatments of the late hockey great Gordie Howe and former professional quarterbacks John Brodie and Bart Starr. (See here and here.)
Randy Mills, head of the California stem cell agency, calls the cash
available for research awards "the big bucket." CIRM graphic
California's ambitious stem cell research agency has $639 million remaining in uncommitted cash as it continues to seek therapies and perhaps cures for afflictions ranging from spinal injury to diabetes.
Randy Mills, president of the 12-year-old program, announced the figure today at a San Diego meeting of the agency's governing board. He also said the program, formally known as the California Institute for Regenerative Medicine (CIRM), is expected to run out of funds in June 2020.
CIRM is financed by money that the state borrows -- $3 billion in bonds approved by California voters in 2004. Using borrowed money also leads to interest costs, increasing the ultimate taxpayer expense to roughly $6 billion. However, that estimate dates back to 2004 and no fresher figure has been produced by the state.
Mills reminded his directors that the agency is allowed only $180 million for operational expenses over the life of the program. About $61 million remains for those expenses.The current annual operational budget of $16 million pays for the roughly 55-person staff to oversee $900 million in active awards and to make new awards.
The agency has handed out $2.1 billion over its life but many of those research efforts are finished. No therapies have been developed for widespread use.
The agency also has a "return rate" of 3 percent to 5 percent on awards. The "return" is cash that is left over from an award or that is returned to the agency when a researcher does not meet research milestones, and the award is cancelled. The returned cash is running at about $40 million annually.
Just what will happen to the agency come 2020 is unclear. Mills today said he and his team are monitoring the funds carefully so that awards and the operational funds run out at the same time.
The agency also may begin lose key staff as time passes and no plan for 2020 emerges, a possibility that Mills has publicly discussed, albeit briefly.
As for future funding, thoughts about another bond issue, public-private partnerships and more legislative funding have been bandied about. But nothing concrete has yet emerged.
Operational funds are described as "the little bucket" by Mills. CIRM graphic
Folks interested in seeing more or less or different federal regulation of stem cell treatments and research have until Sept. 27 to file their arguments with the Food and Drug Administration(FDA) following two days of public hearings earlier this week.
Patients, researchers and representatives of regulated and unregulated companies turned out personally Monday and Tuesday for FDA hearings on its new proposals. Witnesses included Randy Mills, president of the California stem cell agency. Questions were asked by an FDA panel but no conclusions reached.
For those who missed the marathon sessions, they are recorded and are available online. One big advantage of watching them in a recorded format is the ability to skip through the content rapidly instead of having to sit and wait for the whole process to unwind. The first day can be found here and the second here.
The live, online Internet broadcast chalked up about 770 views on the first day. On the second day, only about 550 were reported. The numbers seem low to this writer based on the intense, emotional interest on the part of many patients. Industry also does not seem overly interested despite forecasts of the billions of dollars to be made from regenerative medicine, which may say something about the likelihood of handsome profits.
Only 15 written comments have been filed so far, mostly from patients. That number is likely to increase as industry and academia weigh in with more details.
The FDA has not released a timetable for action which could affect many of the 570 unregulated stem cell clinics operating across the country.
The hearings generated almost no media coverage. However, the Washington Post and Stat published good pieces (see here and here) that provided an overview of the issues ahead of this week's hearing. You can find coverage by the California Stem Cell Reporthere, here, here and here.
California Healthline carried a piece Monday with comments from Mills that basically summarized his presentation to the FDA. Today, the agency's blog carried an item with the text of the Healthline comments. The item by Kevin McCormack, senior director of communications, also said that Mills believes that "the rules the FDA is proposing will not fix the problem, and may even make it worse."
UC Davis stem cell researcher Paul Knoepfler summed up the second day of the hearings in a blog item yesterday. He quoted Leigh Turner, a University of Minnesota bioethicist, as saying,
“The out-of-control marketplace for stem cell interventions needs
effective regulatory oversight. I therefore hope the draft guidances are
more than stage props and this hearing is more than public theater.
When patient safety and public health are at stake, the FDA must do more
than function as a paper tiger. It is time for action.”
A California stem cell researcher has filed a report that chronicles some of the details that help to provide a sharper picture of the events yesterday and today at 9000 Rockville Pike in Bethesda, Maryland.
Writing on The Niche blog, Jeanne Loring, head of the stem cell program at the Scripps Insitute, covered matters -- ranging from aircraft flight to the blind -- that came up at the Food and Drug Administration hearing into new regulation of stem cell therapies. .
Loring is at the hearing, which is underway again this morning, and will testify later today. Her item noted that the marathon yesterday included 42 presentations of five minutes each.
She wrote,
"The question asked by the FDA is 'what should we regulate?' and the
answer from the majority of speakers was 'don’t regulate the things that
we’re doing!'"
Loring continued,
"The clinics, in general, wanted the FDA to define the fat as having
non-structural as well as structural functions. This would allow them to
isolate cells from fat and inject them into the bloodstream, a popular
treatment at many clinics, without FDA oversight.
"There were amusing incidents, such as when Randy Mills (president of the California stem cell agency) used a
metaphor to describe the FDA regulating rapidly developing stem cell
therapies; it was, he said, as if the Wright brothers had just gotten
their plane off the ground, and returned to find an FAA official who
explained that he was going to regulate their planes. I also liked
Arnold Caplan’s 'apology' for naming the stromal cells he extracted from
bone marrow 40 years ago 'mesenchymal stem cells.' They aren’t stem
cells, he said, but rather cells that secrete factors that may be useful
for healing in some cases.
"At the periphery there were the victims of reckless stem cell
clinics. A man wore a sign that said he was blinded by a stem cell
procedure. A woman I met while standing in line for the bathroom told me
that her husband and 6 others had been blinded at a Florida clinic. In
his case, she said, he did not sign the paperwork that would prevent him
from suing the clinic, so they’ve found a lawyer."
Loring predicted that today's session will include much from unregulated clinics. She said,
"From the applause (yesterday) whenever a speaker said they
should not be regulated, I expect that most will be glowing. But I hope,
for balance, that a few will report negative experiences. I haven’t
decided what to say when my time comes (this) afternoon."
The president of the $3 billion California stem cell agency today told federal regulators that patient demand is "very real" for stem cell therapies and called for "alternative" pathways for development.
Randy Mills at FDA hearing
Randy Mills said patients are "really suffering and their needs are not being met." He said the demand is like a flood of water and will find its way around any blockages that rise up.
Mills spoke during the first day of a two-day hearing by the Food and Drug Administration(FDA) into possible new regulation of the stem cell field.
The session came as the Washington Postpublished online a lengthy piece about unregulated stem cell therapies and the increasing scrutiny they are facing from regulators. Reporter Laurie McGinley wrote about a clinic in Beverly Hills with a self-described "Time Machine" box.
Mark Berman, who was described as the co-founder of the "biggest network of commercial stem cell clinics" in the country, processes stems cell through the box for a procedure that he says doesn't require FDA approval.
McGinley wrote,
"In mini-liposuction procedures, Berman extracts fat tissue from patients
and puts it into the Time Machine box, where a centrifuge separates
stem cells from fat. The cells are then injected back into the patients
to supposedly treat a variety of health problems, such as arthritic
knees, heart disease, amyotrophic lateral sclerosis and even autism."
The treatments run about $8,900 each. Berman said his network has treated about 5,000 persons, McGinley reported.
The Post piece said that such treatments and their regulation or lack of regulation has "ignited a fierce debate among physicians, patients, scientists and
politicians about whether the (FDA) should crack down on therapies thatcritics deride as snake oil but that some patients swear by.And it is fueling a broader, longer-term debate over how cellular therapies should be regulated."
Stem cell researcher Paul Knoepfler of UC Davis , who is quoted in the Washington Post article, took in today's FDA hearing from his lab in California. Writing on his blog, he delivered some "take-homes" after the session concluded. Here are a few excerpts from what Knoepfler wrote.
"Some speakers advocated for a 'middle ground' between 'nothing' in the
way of regulation for instance of the dubious clinics and the perceived
'mountainous' extreme of the current FDA oversight system. The middle
ground was, for example, argued for by Janet Marchibroda of the BPC and
then also in the next talk by CIRM President Randy Mills. Mills, who is a very powerful speaker, argued that there is a
harmful binary system now and we need a middle ground between the
extremes of little-to-no regulation and the current in his view
constricted pathway."
"Several speakers invoked patient autonomy and patient rights, and argued
that they are doing what they are doing as practitioners of stem cell
therapies simply for the betterment of patients. There’s the pesky
problem there with this argument of probably millions of dollars in
profit being made from the patients by some clinics though. If it’s all
about patients, I challenge the clinics to do the transplants strictly
'at cost' with no profit margin."
"Many parties asked the FDA for more clarity and consistency on
oversight. Also, a number of speakers asked for concrete, real world
examples of how definitions would apply. I’ve been pushing the FDA for
increased clarity for years including lay abstract summaries of their
main guidelines and statements of current thinking. I really like the
idea of flowcharts."
The nation's leading industry group for regenerative medicine today called for a clearer federal pathway to help bring stem cell products to the marketplace.
The Alliance for Regenerative Medicine (ARM), which has 240 business, academic and patient advocacy members, testified today at a Food and Drug Administration hearing into proposals for more regulation of the stem cell industry. Randy Mills, president of the California stem cell agency, is scheduled to speak later today.
In remarks prepared for delivery, Michael Werner, executive director of the group, said,
"What all manufacturers have in common...is that they seek a clear and predictable regulatory pathway to market. In general, ARM believes that while the draft guidances are a positive step forward, they still leave some questions unanswered regarding interpretation of regulations . Consequently, ARM believes that when FDA finalizes these guidances, it should take actions to provide even more clarity."
Werner went on to make specific suggestions for more explanation on requirements for product characterization and associated claims for each type of product.
The full text of his remarks can be found here. You can find additional information in the texts of the group's comments that were submitted in writing on "minimal manipulation" here and and on "homologous use" here.
The FDA's two-day hearing into stem cell treatments is underway this morning and can be seen live on the Internet, including a presentation this afternoon by the California stem cell agency, which is seeking to ease FDA regulation of stem cell clinical trials.
A likely preview of the comments from the agency popped up this morning on California Healthline in a piece by Emily Bazar. She carried the brief text of an interview with Randy Mills, president of the $3 billion California agency.
He said,
"The problem with (the FDA's current) strategy is twofold. It doesn’t address the
patients, or the need side of the equation. And I don’t think it has a
chance of actually working because the FDA will acknowledge that they do
not have the resources to enforce these types of regulations at the
clinic level.
"They would have to be essentially regulating the practice of
physicians, which is well beyond their capabilities. Even if they were
able to enforce it, it would just drive these patients somewhere else.
"We’re advocating for the creation of some middle pathway that would
bring essentially unregulated therapies into the regulatory fold, but in
a manner which could be complied with.
"I would rather know these clinics are being regulated and collecting
data than have them operating under the radar screen of the FDA. I would
like there to be a formal pre-market review of these therapies before
they’re put on the market. I would like there to be safety and efficacy
data.
"I’m going to try hard to get the FDA to see that just plugging this hole won’t make the problem go away."
Bazar's piece also contained the text of comments from Jeanne Loring, head of the stem cell research program at the Scripps Institute in La Jolla. She said,
"There’s no scientific evidence that the fat cells (unregulated) clinics are
using are going to do the patient any good. And there’s no evidence that
shows they are safe.
"I’m a stem cell scientist. I need scientific evidence before I will
believe anything. Regulation will help determine the efficacy and safety
of those fat cells.
"There are several lawsuits or potential lawsuits brewing over these
stem cell treatments. People were promised they would get improvements
and didn’t. And there are cases where people were actually harmed by
stem cells.
"Some people truly believe they have been helped by the stem cell
injections. I’m not going to argue with them. It’s a very personal and
emotional response. It’s not something that can be scientifically
validated. People are really desperate, especially really sick people
and their families.
"That means patients are at risk. That’s what bothers me a lot.
There’s nothing we can do to talk somebody out of going to a clinic if
they feel that’s the only option they have. We just want to make sure
nobody gets hurt. We also don’t want people to go broke. These
treatments are not covered by insurance and they cost tens of thousands
of dollars."
Here is a link to the actual broadcast, which is being watched by about 300 persons at this moment. An overview of the audience seems to indicate that it is being lightly attended. Mills is scheduled to speak at 4:23 p.m. EDT.
Here is a link to the agenda including a list of speakers and schedule. The broadcast also has closed caption capability.
The Center for Genetics and Society, a longtime critic of the California stem cell agency, yesterday described the Trounson-StemCells, Inc., affair as "scandalous" and part of an "object lesson" in how not to set up a state agency.
Writing on center's blog, Pete Shanks referred to the disclosure that Alan Trounson, former president of the $3 billion research effort, had received $443,500 in total compensation from StemCells, Inc., of Newark, Ca., for his work on the company's board over a two-year period. Trounson was appointed seven days after leaving the agency, which came as an unpleasant surprise to the stem cell agency's governing board.
StemCells, Inc., was awarded $40 million while Trounson was president of the California Institute for Regenerative Medicine (CIRM), as the agency is formally known.
"Did Trounson or StemCells Inc. do anything illegal? Quite likely not.
Was this transaction appropriate? Absolutely not! It’s scandalous, but
it’s the kind of scandal that was built into CIRM from its very
inception."
Shanks recounted the conflict-of-interest issues that have troubled the agency even prior to voter approval of the program. He concluded,
"CIRM is now slowly running out of the $3 billion of public funds
allocated to it in 2004, and is expected to wind up in 2020. It has
provided an object lesson in how not to set up and run an
independent public-funded agency. These latest revelations should end
any speculation about extending its charter."
Stanford University stem cell researcher Irv Weissman has sent along the following comment in the wake of the publication of the Sept. 2, 2016, story concerning Alan Trounson's compensation from StemCells, Inc., a company co-founded by Weissman, who also served on its board of directors.
"I would like to correct some information that can be verified by CIRM officials and employees. I have known Alan Trounson for years before he came to CIRM both as a scientist and once on a fishing trip. After he got settled into his position at CIRM we met socially, and agreed to go on another fishing trip together. From that time forward he recused himself on all grants and CIRM related activities that involved either my lab or Stem Cells Inc. This was unfortunate for me, as there were times when he was the field expert and could have suggested appropriate reviewers, or mistakes in review, for grants coming from me at Stanford or Stem Cells, Inc. Although you mention the many successes we have had with CIRM grants, there were many more times when I failed to reach a funding score that was sufficient, sometimes with what I thought were inaccurate reviews,and sometimes with reviewers that I would have asked to be removed for conflicts outside of scientific expertise. I am happy to answer any questions on these issues for all grants on which I am a principal investigator, or as on the stem cell genomics grant, a participating but minor investigator who was the only person with purified stem and progenitor cells.
"I hope you dig into the actual current value of his or my stock, so that the public will know the real numbers. At least up to the wind-down of the company I believe I have never sold stock I hold, as I felt I always could have had information not generally available to the public, even when it was legal by SEC standards. In the early days of the company I contributed personal money to the company for stock so that the company could meet its payroll, and also I never sold those stocks. All of my SCI stocks are worth no more than and probably much less than 10% of that single contribution."
